MS disability worsened more slowly in recent years

Credibility

Interest

Share:1 min read

Key Takeaway

Disability worsened more slowly in people diagnosed with relapsing MS more recently, including worsening that happened without a relapse.

What They Found

Researchers compared disability scores for people diagnosed with relapsing MS in different periods. Both relapse-related worsening and worsening without a relapse were lower in more recent groups. Worsening without a relapse made up most of the overall disability increase in every group. Its share rose from about 78% in the earliest group to about 87% in the latest group. The researchers concluded that the slower rise in disability reflected less worsening of both kinds.

Who Should Care and Why

The study included people diagnosed with relapsing-remitting MS at an MS center in Italy. Some were diagnosed before MS treatments became available. Others were diagnosed during later periods when more treatment options were available. The study compared how their disability scores changed over time. It found that worsening without a relapse remained a major part of those changes.

Important Considerations

Researchers looked back at records for 1,405 people at one MS center in Italy. You cannot tell from this study whether newer treatments caused the slower worsening. The study measured changes in disability scores, not every effect MS can have on daily life.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News